MR-Consulting
Independent strategic consultancy (est. 2010) advising pharmaceutical, biotech and medical-technology companies on market access, public reimbursement and pricing in Israel. Core services include market-access strategy, preparation and submission of reimbursement dossiers for national public payers, health-economic evaluation (budget-impact and cost-effectiveness), DRG/tariff advisory, design of risk-sharing and outcomes-based agreements, epidemiology and market-sizing, and support through formal inclusion and committee processes.
Industries
Nr. of Employees
small (1-50)
MR-Consulting
ת.ד 595, נס ציונה 7410402, Israel
Products
Strategic Consulting in Market Access
Provides strategic advice for introducing medical products like drugs and technologies into public healthcare funding systems.
Preparation of Submission Dossiers for the National Health Services Basket
Assists in building and preparing detailed submission dossiers for inclusion of drugs and medical technologies in the national health services basket.
Support for Inclusion Processes of Drugs and Medical Technologies in the National Health Services Basket
Provides guidance and assistance throughout the process of including drugs and medical technologies in the national health services basket.
Economic Evaluation of Drugs and Medical Technologies
Conducts budget impact analyses and cost-effectiveness evaluations for drugs and medical technologies.
Consulting on Differential Diagnosis-Related Group (DRG) Coding for Hospital Technologies
Advises on the assignment of differential DRG codes and pricing for inpatient medical technologies.
Consulting on Pricing Strategy for Medical Products
Offers advice on pricing strategies for pharmaceutical products, medical devices, and equipment.
Strategic Consulting in Market Access
Provides strategic advice for introducing medical products like drugs and technologies into public healthcare funding systems.
Preparation of Submission Dossiers for the National Health Services Basket
Assists in building and preparing detailed submission dossiers for inclusion of drugs and medical technologies in the national health services basket.
Support for Inclusion Processes of Drugs and Medical Technologies in the National Health Services Basket
Provides guidance and assistance throughout the process of including drugs and medical technologies in the national health services basket.
Economic Evaluation of Drugs and Medical Technologies
Conducts budget impact analyses and cost-effectiveness evaluations for drugs and medical technologies.
Consulting on Differential Diagnosis-Related Group (DRG) Coding for Hospital Technologies
Advises on the assignment of differential DRG codes and pricing for inpatient medical technologies.
Consulting on Pricing Strategy for Medical Products
Offers advice on pricing strategies for pharmaceutical products, medical devices, and equipment.
Services
Strategic planning for introducing medicines, devices and technologies to public funding pathways and other payer channels in Israel.
End-to-end compilation of clinical, epidemiological and economic documentation required for submission to national and payer committees.
Preparation of budget impact analyses, cost-effectiveness and cost-utility studies to support reimbursement, pricing and prioritization decisions; includes per-patient and population-level scenarios.
Advisory on structuring commercial and outcomes-based contracts, including specification of measurable outcomes, data-collection plans and operational considerations.
Consulting on differential DRG code assignment and tariff submissions to align hospital coding with reimbursement strategy.
Strategic planning for introducing medicines, devices and technologies to public funding pathways and other payer channels in Israel.
End-to-end compilation of clinical, epidemiological and economic documentation required for submission to national and payer committees.
Preparation of budget impact analyses, cost-effectiveness and cost-utility studies to support reimbursement, pricing and prioritization decisions; includes per-patient and population-level scenarios.
Advisory on structuring commercial and outcomes-based contracts, including specification of measurable outcomes, data-collection plans and operational considerations.
Consulting on differential DRG code assignment and tariff submissions to align hospital coding with reimbursement strategy.
Expertise Areas
- Market access and reimbursement strategy
- Reimbursement dossier preparation for public payers
- Health economic evaluation (BIA, CEA, CUA)
- Health technology assessment (HTA) and policy analysis
Key Technologies
- Budget impact modelling
- Cost-effectiveness modelling (CEA, ICER)
- Cost-utility analysis (CUA, QALY)
- Real-world evidence generation and analysis
News & Updates
Summary of a market-access conference covering the national health-basket process, risk-sharing agreements, oncology developments and real-world data implications.
Editorial discussing clinical results and reimbursement and regulatory considerations for an expensive biologic therapy.
Summary and link to a published cost-effectiveness analysis of rotavirus vaccination for an Israeli birth cohort.
Overview of the 2018 national health-basket update including budget, submission volumes and major therapeutic areas funded.
Research estimating the fiscal impact of new medical technologies on public healthcare expenditures in Israel between 2000 and 2007; includes downloadable PDF.
Summary of a market-access conference covering the national health-basket process, risk-sharing agreements, oncology developments and real-world data implications.
Editorial discussing clinical results and reimbursement and regulatory considerations for an expensive biologic therapy.
Summary and link to a published cost-effectiveness analysis of rotavirus vaccination for an Israeli birth cohort.
Overview of the 2018 national health-basket update including budget, submission volumes and major therapeutic areas funded.
Research estimating the fiscal impact of new medical technologies on public healthcare expenditures in Israel between 2000 and 2007; includes downloadable PDF.